CRLF2 and acute lymphoblastic leukemia: In conclusion, we show here that CRLF2 over-expression is a poor prognostic marker in T-ALL, identifying a subset of HR T-ALL patients that could be eligible for alternative therapies, including those that interfere with the activation of JAK/STAT5 signaling pathway.